Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Block C - Circulation > Pharmacology Lecture 4: Anticoagulant and Fibrinolytic Drugs > Flashcards

Pharmacology Lecture 4: Anticoagulant and Fibrinolytic Drugs Flashcards

(88 cards)

Start Studying
1
Q

Purpose of anticoagulants and fibrinolytic drugs

A

Treat or prevent thromboembolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Behavior of blood in normal individual in terms of clotting

A

Blood remains fluid in vessels
Clot when vascular injury occurs
If intravascular thromus is formed, prompt dissolution by a fibrinolytic system
Hemostasis in damaged vessels if bleeding occurs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

5 anticoagulant drugs of interest

A

Heparin
Low molecular weight heparing
Oral antiagulants (dabigatran, rivaroxaban, warfarin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

2 fibrinolytic drugs of interest

A

Streptokinase

Alteplase (recombinant tissue plasminogen activator)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Define heparin

A

Mixture of sulphated mucopolysaccharides from mast cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Heparin function

A

Acts as a cofactor for antithrombin (III) = increase rate of thrombin-antithrombin reaction at least a thousand fold

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Location of antithrombin production

A

Liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Antithrombin function

A

Inhibit activated coagulation factors of the intrinsic and common pathways, most importantly thrombin and factor Xa. Acts as a suicide substrate for these proteases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How unfractionated heparin is obtained

A

From mast-cell rich tissues in animals (endogenous)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How are doses of unfractionated heparin expressed and why?

A

Units of activity (USP units) because biological activity is similar across commercial preparations despite differences in composition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How to administer heparin

A

Must be injected (given parenterally) because cannot be absorbed through the gastrointestinal mucosa. Usually by continuous vascular infusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Speed of onset if heparin is given by I.V.

A

Immediate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Speed of onset if heparin is given subcutaneously and consequence

A

Delayed by 1-2 hours

Considerable variation in bioavailability due to macrophage destruction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Define how the pharmacokinetics of heparin is saturatable

A

Most of it is cleared and degraded by the reticulo-endothelial system (fixed amount of macrophages), with a small amount unaltered in the urine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Define continuous vascular infusion

A

Bolus injection followed by maintenance dose delivered by infusion pump

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How to monitor heparin in patient who had continuous vascular infusion

A

Activate partial thromboplastin time (aPTT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How to monitor subcutaneously administrated heparin

A

Once a stable value of aPTT is obtained, can stop lab monitoring

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

When is unfractionated intravenous heparin used?

A

In hospitalized patients for initial management of pulmonary embolism following DVT and of DVT above knee joint.
Unstable angina and MI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

When is unfractionated subcutaneous heparin sometimes used?

A

Bed-ridden or hospitalized patients not receiving intravenous heparin for prevention of DVT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

5 side effects of unfractionated heparing (toxicity)

A 
Bleeding
Thrombocytopenia
Allergies
Increased loss of hair (reversible)
Risk of osteoporosis with prolonged therapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

How to prevent bleeding due to unfractionate heparin

A

Adequate patient selection
Careful control of dosage
Close monitoring of aPTT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

How common is early transient and harmless thrombocytopenia in unfractionated heparin patients? What is the cause?

A

25% due to platelet aggregation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Potential effect in up to 5% of patients on unfractionated heparin following 5 - 15 days of treatment. What is the significance of this?

A

Development of heparin-induced anti-platelet antibodies (HIT), which can lead to serious bleeding and paradoxical clotting (medical emergency; important to perform frequent platelet counts)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Contraindications for heparin use

A

Thrombocytopenia, bleeding disorders, active peptic ulcer disease, severe hypertension, etc.

Does not cross placenta, but still try to avoid in pregnancy unless necessary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Heparin antagonist
Protamine sulfate
26
When are heparin antagonists required?
Only if bleeding is significant (not for minor bleeding since effects will disappear in a few hours after last injection)
27
How does protamine sulfate inactivate heparin?
By binding tightly to it
28
What is replaced unfractionated heparin in many applications
Low molecular weight (LMW) heparin
29
LMW heparin function
Main effect through a catalytic effect on the inhibition of factor Xa (not thrombin) by antithrombin Less effect on coagulation in general, but comparable to unfractionated heparin in most cases
30
2 examples of LMW heparin preparations
Enoxaparin | Dalteparin
31
How to administer LMW heparin
Given subcutaneously in fixed or weight adjusted dosage once or twice daily
32
Risk of HIT in LMW heparin
Significantly lower than with unfractionated heparin so monitoring not usually required since pharmacokinetics more predictable
33
Novelty heparin replacement
Synthetic selective inhibitors of factor Xa (i.e. fondaparinux)
34
How to administer fondaparinux
Subcutaneously once a day without monitorinf
35
Problem with fondaparinux
Expensive and no antagonist available yet
36
How was warfarin synthesized/discovered?
1924: Hemorrhagic disorder found in cattle that had ingested spoiled sweet clover silage 1939: Agent identified as dicoumarol 1948: warfarin synthesized
37
What was warfarin's initial use?
Rat poison
38
What coagulation factors and anticoagulant proteins are produced mainly in the liver?
Factors II, VII, IX, X | Anticoagulant proteins C and S
39
What do the coagulation factors and anticoagulant proteins produced in the liver require and why?
Reduced vitamin K for the carboxylation of certain glutamate residues
40
What is the consequence of vitamin K absence on coagulation factors?
Abnormal coagulation factors of formed = do not work
41
What is the speed of full onset of warfarin effect? Why?
A few days since some factors have very long half lives (i.e. 50 hour for factor II)
42
How to administer warfarin
Well absorbed orally
43
Speed of plasma detection and concentration peaks
Plasma detection = 1 hour | Peak = 2 - 8 hours
44
What does warfarin bind to?
Plasma proteins
45
Warfarin and pregnancy
Avoid at all costs since it crosses the placenta easily --> bleeding in fetus and malformations
46
Where is warfarin metabolized and into what?
Metabolized into inactive metabolites in liver and kidney
47
Plasma half life of warfarin
Varies from 25 - 60 hours (average 40)
48
Duration of warfarin action
2 - 5 days
49
What do we use to monitor warfarin?
INR (international normalized ratio)
50
Why is it important to maintain a therapeutic INR level?
For effective therapy and to reduced bleeding complications
51
Clinical uses of warfarin
Long term anti-coagulation Prevent progression or recurrence of DVT above knee joint (w/ or w/o PE complications) after initial heparin treatment Indefinitely to prevent strokes in atrial fib. or prosthetic valve patients
52
How to pharmacologically treat DVT above knee joint complicated or not with pulmonary embolism
Initially LMW heparin for 7-10 days as it overlaps with warfarin for 3 - 5 days (since onset of action is slow)
53
How long is warfarin treatment kept for?
3 - 6 months
54
Major toxicity of coumarin anticoagulants such as warfarin
Bleeding
55
Important cause of bleeding with warfarin
Drug interactions
56
How to treat patient with bleeding due to warfarin
Give fresh plasma or coagulation factor concentrates and vitamin K1
57
Conditions or drugs are potentially dangerous in patients taking warfarin is they alter (3)...
Uptake or metabolism of warfarin or vitamin K Synthesis, function or clearance of clotting factors and other elements involved in hemostasis or fibrinolysis Integrity of epithelia
58
New oral anticoagulants
Dabigatran Rivaroxaban Apixaban
59
Purpose of new oral anticoagulants
Improve the ease of use, safety and efficacy of oral anticoagulants
60
Dabigatran function
Direct thrombin inhibitor
61
How is dabigatran administered?
As a prodrug (dabigatran etexilate) --> broken down in the body to dabigatran Lab monitoring not required
62
Onset and half-life of dabigatran
Rapid onset | Plasma half-life = 12 - 16 hours (in patients with normal renal function)
63
Current approval for dabigatran
Prevention of stroke in patients with non-valvular atrial fib Prevent thromboembolism in patients who have undergone hip or knee replacement surgery
64
Advantage of dabigatran over warfarin
Incidence of bleeding is the same or better | No experience in pregnancy (but doesnt mean no effect)
65
Disadvantage of dabigatran relative to warfarin
More expensive | No specific antagonist yet (in clinical trials)
66
Rivaroxaban function
Direct factor Xa inhibitor
67
Rivaroxaban uses
Prevention/treatment of pulmonary embolism, DVT Prevention of stroke in patients with atrial fib Prevention of thromboembolism after knee or hip replacement surgery
68
What does drug elimination depend on for rivaroxaban?
Renal function
69
What is the status of the bleeding risk profile of rivaroxaban?
Acceptable
70
Disadvantage of rivaroxaban
No specific antagonist yet | No experience in pregnancy
71
Apixaban function
Factor Xa inhibitor (most recently approved)
72
What has apixaban been approved for?
Prevention of stroke in patients with non-valvular atrial fib Prevent thromboembolism in patients who have undergone hip or knee replacement surgery
73
General function of fibrinolytic drugs
Catalyse the formation of plasmin from plasminogen, leading to the lysis of thrombi
74
Effect of fibrinolytic drugs given intravenously
Generalized lysis of thrombi = BOTH of the protective hemostatic thrombi AND targeted pathological thrombi
75
Define streptokinase
Protein synthesized by B-hemolytic streptococci
76
Disadvantage of streptokinase
Risk of serious allergic reaction when given a second time, so rarely used today
77
Define alteplase
Recombinant tissue plasminogen activator (tPA)
78
Alteplase function
Preferentially activate plasminogen bound to fibrin | Theoretically limits fibrinolysis to formed thrombi to avoid systemic activation
79
How to administer alteplase
Intravenous infusion
80
Define tenecteplase
A mutant form of tPA with a longer half-life
81
How to administer tenecteplase
Bolus injection (rather than IV infusion since longer half-life)
82
Clinical uses of fibrinolytic drugs (4)
1) Acute MI with ST elevation (first 6 hours after infarction, particularly if percutaneous coronary intervention not available) 2) Large (or multiple) pulmonary emboli 3) Dissolve clots in blocked central catheters 4) Ischemic stroke (first 3 hours)
83
Subsequent treatment after administering fibrinolytic drugs
Aspirin and clopidogrel
84
Major risks of fibrinolytic drugs
Hemorrhage | Conversion of an ischemic stroke into a hemorrhagic stroke
85
2 mechanisms by which fibrinolytic drugs cause hemorrhage
Lysis of "physiological" thrombi | Induction of a systemic lytic state
86
Antagonist for fibrinolytic drugs
Aminocaproic acid
87
Aminocaproic acid
Block the binding of plasmin to fibrin = stop bleeding due to fibrinolytic drugs (not devoid of risks)
88
Contraindications for fibrinolytic drugs (6)
1) Recent surgery 2) Serious gastro-intestinal bleeding in last 3 months 3) Hypertension 4) Active bleeding or hemorrhagic disorder 5) Previous cerebrovascular event 6) Aortic dissection or acute pericarditis

Block C - Circulation (26 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions